SecBot SecBot
8-K ·Filed Apr 9, 2026

TMCI

TREACE MEDICAL CONCEPTS, INC.
MIXED
Impact 6/10
Horizonweeks Processed7mo ago SEC0001630627-26-000010
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor the Q1 earnings call for confirmation of preliminary results and commentary on the CCO departure; the modest guidance lift may not offset decelerating sequential revenue.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.53
T+0 close · Apr 9, 2026 · via day close
Latest settled
+198.04%
T+60 · $4.56
Vs SPY
+187.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $1.53entry
  2. T+1 · 7mo ago +18.30%α +18.36% · $1.81
  3. T+5 · 7mo ago +22.22%α +19.04% · $1.87
  4. T+20 · 7mo ago +26.14%α +18.58% · $1.93
  5. T+60 · 4mo ago +198.04%α +187.26% · $4.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Treace Medical Concepts issued a preliminary Q1 2026 outlook showing revenue of $47.0–47.2M and cash rising to $51.9M, while updating full-year 2026 revenue guidance to $202–212M. The Chief Commercial Officer departed and will transition to a consulting role, with responsibilities absorbed internally.

Key Financial Metrics

Revenue
$47.1M
est $46.0M · +2.4%
Guidance
$202M-$212M
raised

Key Facts

  • Preliminary Q1 2026 revenue: $47.0–47.2 million
  • Cash, cash equivalents, and marketable securities expected to be ~$51.9 million as of March 31, 2026, up from $48.4 million at year-end
  • Updated full-year 2026 revenue guidance raised to $202–212 million (from $200–212 million)
  • Chief Commercial Officer Gaetano Guglielmino departed; no replacement planned; responsibilities reassigned
  • Guglielmino to serve as consultant through January 31, 2027, receiving $36,666.67/month and other benefits

Financial Impact

Revenue guidance increase of $2M at midpoint; preliminary Q1 revenue implies sequential decline from Q4 2025's $62.5M

revenuecashoperating expenses

Risk Factors

  • Preliminary Q1 revenue suggests a sequential decline from Q4 2025 ($62.5M), indicating potential weakening demand
  • Departure of Chief Commercial Officer without replacement raises questions about commercial strategy execution

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001630627-26-000010
Document: 0001630627-26-000010-index-headers.html0001630627-26-000010
Document: 0001630627-26-000010-index.html0001630627-26-000010
Document: 0001630627-26-000010.txt0001630627-26-000010
8-K Data (Synthetic)0001630627-26-000010

Track record

11 reports on TMCI

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +12.39% at T+60 after the Jul 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 20261d ago SC 13G Neutral 4/10 Entry $4.42 to $4.44 Now $4.44 +0.45% ▲ +0.45% +1.47% vs SPY
  2. Nov 16, 20261d ago SC 13G/A Bearish 4/10 Entry $4.42 to $4.44 Now $4.44 −0.45% ▼ −0.45% −1.47% vs SPY
  3. Nov 12, 20266d ago Court Ruling Neutral 4/10 Entry $5.27 to $4.42 Now $4.44 −15.75% ▼ −16.13% −14.22% vs SPY
  4. Nov 6, 202611d ago 8-K Neutral 4/10 Entry $4.03 to $4.78 Now $4.44 +10.17% ▲ +18.61% +16.24% vs SPY
  5. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $4.49 to $4.48 Now $4.44 −1.11% ▼ −0.22% −1.77% vs SPY
  6. Aug 7, 202614w ago 8-K Mixed 6/10 Entry $4.76 to $4.67 Now $4.44 −6.72% ▼ −1.89% −1.86% vs SPY
  7. Jul 13, 202618w ago Court Ruling Bearish 5/10 Entry $4.44 to $4.40 Now $4.44 −0.00% ▲ +0.90% +1.30% vs SPY
  8. May 8, 202627w ago Press Release Bearish 7/10 Entry $2.01 to $1.94 Now $4.44 −120.90% ▲ +3.48% +3.71% vs SPY
  9. Apr 24, 202629w ago Press Release Neutral 1/10 Entry $1.98 to $1.92 Now $4.44 +124.24% ▼ −3.03% −3.19% vs SPY
  10. Apr 9, 202631w ago 8-K Mixed 6/10 Viewing Entry $1.53 to $1.81 Now $4.44 +190.20% ▲ +18.30% +18.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Thu (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026